Holista Colltech (ASX:HCT) scaling new heights with milestones across divisions - Kalkine Media

Highlights

• Holista Colltech specialises in health and wellness solutions developed using a blend of the best of nature and science.
• Today, Holista has emerged as a strong player in the US$4.4 trillion global health and wellness industry.
• The company recorded revenue growth of 26% in 1H22, driven by double-digit growth in its two largest divisions.
• HCT expects improved FY22 results over FY21, backed by launch of new products, international partnerships, easing macroeconomic headwinds, and several other growth drivers.

Holista Colltech Limited (ASX:HCT), an innovator in health and wellness solutions, is on a passionate drive to bring forth products with a blend of the best of nature and science. With every new range of product, the company looks forward to address evolving needs of the people with which they may live better and healthier lives.   

After a fine-crafted research & development at its four business units, HCT offers its health supplements, ovine collagen, low-GI food ingredients, and all-natural and non-toxic effective sanitisers for consumers and industrial applications.

While the company remains in buzz for its new innovations and success stories, there are some interesting things which deserve public eye in the present time. Have a look!

1. Today, Holista Colltech stands as a strong player in the US$4.4 trillion global health and wellness industry. The ASX-listed company is going strong in the current year following an encouraging finish to 2021. There has been a strong rebound from the impact of COVID-19 on HCT performance. In the first half of 2022, the company recorded 25.6% year-on-year revenue growth. Holista’s pre-tax net loss improved by 33.4%, with double-digit growth in sales registered by its two largest divisions. The company expects this momentum to continue in to the second half.

To learn more, click here

2. Holista is the only company that produces Australian-made sheep collagen extracted using a patented process. Its product is culturally acceptable, fully traceable, and untainted by Foot-and-Mouth Disease and scrapie (related to Mad Cow Disease for sheep).. To expand and strengthen its foothold in the overseas market, the company has appointed exclusive distributor for cosmetic collagen in China.

Image Source: Company Website

Chinese state-owned enterprise Guangzhou Sinbio Cosmetic Co is working to start trials using Holista’s collagen for its cosmetics. Based on the results of the trials, which have been slowed due to China going in and out of lockdowns, a sales agreement is likely between Sinbio and HCT.

3. Dietary Supplements is the largest business unit of the company, recording 34% sales growth in 1H22. Few of the factors that led to the standout performance were Holista’s brand leadership position in this market, easing social restrictions in Malaysia, and growing consumer focus on boosting their health and immunity through supplements.

Image Source: Company Website

The ASX-listed firm is involved in marketing, distribution, and sale of around 37 different propriety supplements. Its growth is likely to boost further with new suite of products, such as water-soluble vitamin D and In2Bloc.

4. The primary offerings under Holista’s Healthy Food Ingredients division contributed strongly to the 1H22 result. Low glycaemic index (GI) premix, GI Lite^TM, and its sugar substitute, 80Less^TM have made a name for themselves in the market. Same is reflected from the company’s contract for these two offerings with Country Farms Sdn Bhd, which is owned by Malaysian conglomerate Berjaya Corporation Berhad, the owner of several international franchises in Malaysia, including Starbucks and 7-Eleven.

5. Under its newest and smallest division, Infection Control, Holista is awaiting TGA approval for its disinfectant, which is proven to kill SARS-CoV2, the virus that causes COVID-19. Moreover, the company’s all-natural Super Bio Nano Silver disinfectant has shown efficacy in killing 99.99% of the human coronavirus.

Stock information: HCT shares traded at AU$0.035 on 12 September 2022. The company has a market capitalisation of AU$11.15 million.